Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Safety of Levornidazole Disodium Phosphate in Subjects With Renal Impairment
NCT07033182Phase 1Completed
- Sponsor
- Yangtze River Pharmaceutical Group
- Start
- Oct 2023
- Primary completion
- Apr 2024
- Modality
- DNA Intercalators/Alkylators, Orthosteric Ligands, Light/Condition-Responsive Prodrugs
- Countries
- 1
01
Overview
Phase 1, open-label trial of levornidazole in anaerobic infection (3 arms), sponsored by Yangtze River Pharmaceutical Group. Primary endpoints: Area Under the Plasma Concentration-time Curve From Time 0 to the Last Measurable Concentration, Area Under the Plasma Concentration-time Curve From Time 0 Extrapolated to Infinity and 9 more. Started Oct 2023; status: completed.
02
Drugs
levornidazole
03
Conditions
anaerobic infection
Beyond the preview
Go deeper on NCT07033182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07033182.